361 Capital’s Quest Diagnostics DGX Stock Holding History

361 Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$726K	Buy	+6,372	New	+$676K	0.34%	146
2019 Q4	–	Sell	-6,551	Closed	-$701K	–	333
2019 Q3	$701K	Buy	+6,551	New	+$673K	0.13%	240
2017 Q3	–	Sell	-18,610	Closed	-$2.07M	–	260
2017 Q2	$2.07M	Buy	18,610 +9,651	+108%	+$1.02M	0.35%	84
2017 Q1	$880K	Buy	+8,959	New	+$854K	0.19%	101

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

361 Capital's DGX Position: Q2 2020 in Review

361 Capital opened a new position in Quest Diagnostics (DGX) in Q2 2020: 6,372 shares worth $726K. The stake represents 0.34% of the portfolio and ranks #146 among its holdings. This is a return to the name: 361 Capital previously reported a position in DGX as recently as Q3 2019.

361 Capital first reported a position in DGX in Q1 2017 and has held it in 4 quarters since. The position peaked at $2.07M in Q2 2017. 749 funds tracked by Wall St. Rank hold DGX as of Q2 2020.

361 Capital held 6,372 shares of Quest Diagnostics worth $726K as of Q2 2020.
Quest Diagnostics was a new 361 Capital position in Q2 2020.
Quest Diagnostics made up 0.34% of 361 Capital's portfolio in Q2 2020, its #146 holding.
361 Capital first reported a position in Quest Diagnostics in Q1 2017 and has held it in 4 quarters since.
361 Capital's Quest Diagnostics position peaked at $2.07M in Q2 2017.
749 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.